New research suggests that young patients with acute lymphocytic leukemia (ALL)—the most common type of pediatric cancer—and their parents are likely to report to their physician that they took more of their anticancer medication than they actually did.
The study, published by Landier et al in Blood,1 reported that 84% of patients with ALL or their parents overreported adherence to a regimen of mercaptopurine (Purixan), an oral maintenance therapy for pediatric ALL. Physicians prescribe mercaptopurine for 2 years after chemotherapy for patients to achieve durable remissions, but studies have shown that over 95% of prescribed doses must be taken to be effective.
Findings from this study suggest that we need better ways to monitor intake of medications as prescribed.— Smita Bhatia, MD, MPH
“Because this therapy is administered orally every day, we cannot supervise our patients to make sure they are taking their pills,” said senior study author Smita Bhatia, MD, MPH, of the University of Alabama at Birmingham. “Findings from this study suggest that we need better ways to monitor intake of medications as prescribed.”
This study builds on trends observed among children with chronic illness with at-home treatment regimens and is the first to directly compare self-reporting against electronic monitoring in pediatric cancer patients.
Study Details and Findings
The study included 416 pediatric ALL patients from 87 participating institutions across the United States. The prescription pill bottles for mercaptopurine contained a microprocessor chip in the cap to log the date and time the bottle was opened. These logs were then compared against self-report questionnaires completed by patients or their parents and provided to their physicians at monthly checkups.
In addition to observing a majority of patients overreporting the number of days they had taken their medications, researchers observed a direct inverse trend in overreporting. Of those found to adhere to their regimens (defined as taking their prescribed dose 95% of the time), a small percentage (8%) overreported their intake. However, among those found nonadherent, a substantially larger percent (47%) overreported.
“We observed that there was an inverse relationship between overreporting and the extent of nonadherence,” said Dr. Bhatia.
Improving Adherence With Parental Involvement
We found that partnering with a parent was very conducive to our patients’ adherence, playing a key role in combatting forgetfulness.— Wendy Landier, PhD, RN
To find out why patients were not taking their prescribed medication, lead study author Wendy Landier, PhD, RN, also of the University of Alabama at Birmingham, organized separate one-on-one interviews with patients and their parents. In these interviews, Dr. Landier noted that forgetfulness was the primary reason for nonadherence. “We found that partnering with a parent was very conducive to our patients’ adherence, playing a key role in combatting forgetfulness,” said Dr. Landier.
Recognizing the importance of parental involvement in patient adherence, the team was inspired to conduct further research to make parents more involved. In a trial that builds on this study, physicians send personalized text messages to both patients and their parents at a prescribed time reminding them to take their medicine. Both the patient and parents then report back, via text, that the indicated dose was taken.
“Our first study showed that nonadherence was prevalent, increasing the risk of relapse. We then found that parental vigilance was an important facilitator to adherence, while forgetting to take the medication was the most commonly reported barrier. We used these findings to inform the intervention trial to help families improve adherence to treatment. We hope that this will be a real step in improving outcomes in children with leukemia,” said Dr. Bhatia. ■
Disclosure: For full disclosures of the study authors, visit www.bloodjournal.org.
1. Landier W, Chen Y, Hageman L, et al: Comparison of self-report and electronic monitoring of 6MP intake in childhood ALL: A Children’s Oncology Group study. Blood. February 2, 2017 (early release online).